These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37210228)

  • 41. Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?
    Salvatore D; Pepe A; Carnovale V; Majo F; Padoan R; Quattrucci S; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
    J Cyst Fibros; 2022 May; 21(3):544-548. PubMed ID: 34583889
    [No Abstract]   [Full Text] [Related]  

  • 42. Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis.
    Anderson A; McCoy L; Pettit RS; Wright BA; Lubsch L
    Pediatr Pulmonol; 2021 Dec; 56(12):4053-4054. PubMed ID: 34499822
    [No Abstract]   [Full Text] [Related]  

  • 43. Regarding the article entitled "Effect of elexacaftor/tezacaftor/ivacaftor on annual rate of lung function decline in people with cystic fibrosis".
    Hoo ZH; Lai LY; Sandler RD; Daniels TE; Dawson S; Hutchings M; Wildman MJ
    J Cyst Fibros; 2023 May; 22(3):587. PubMed ID: 36948912
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
    Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
    Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
    [No Abstract]   [Full Text] [Related]  

  • 45. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
    Davies JC; Sermet-Gaudelus I; Naehrlich L; Harris RS; Campbell D; Ahluwalia N; Short C; Haseltine E; Panorchan P; Saunders C; Owen CA; Wainwright CE;
    J Cyst Fibros; 2021 Jan; 20(1):68-77. PubMed ID: 32967799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis.
    Petersen MC; Begnel L; Wallendorf M; Litvin M
    J Cyst Fibros; 2022 Mar; 21(2):265-271. PubMed ID: 34862121
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis.
    Causer AJ; Shute JK; Cummings MH; Shepherd AI; Wallbanks SR; Pulsford RM; Bright V; Connett G; Saynor ZL
    Pediatr Pulmonol; 2022 Nov; 57(11):2652-2658. PubMed ID: 35851858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
    Schwarz C; Sutharsan S; Epaud R; Klingsberg RC; Fischer R; Rowe SM; Audhya PK; Ahluwalia N; You X; Ferro TJ; Duncan ME; Bruinsma BG
    J Cyst Fibros; 2021 Mar; 20(2):228-233. PubMed ID: 32586736
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.
    Gramegna A; Contarini M; Bindo F; Aliberti S; Blasi F
    Curr Opin Pharmacol; 2021 Apr; 57():81-88. PubMed ID: 33582393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.
    Martin C; Reynaud-Gaubert M; Hamidfar R; Durieu I; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Lemonnier L; Burnet E; Paillasseur JL; Da Silva J; Burgel PR
    J Cyst Fibros; 2022 May; 21(3):489-496. PubMed ID: 35123901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children.
    Nathan N; Thouvenin G; Dubern B; Corvol H
    Pediatr Pulmonol; 2024 Mar; 59(3):788-790. PubMed ID: 38088210
    [No Abstract]   [Full Text] [Related]  

  • 53. Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population.
    Smith S; Borchardt M
    J Manag Care Spec Pharm; 2022 Jul; 28(7):721-731. PubMed ID: 35737861
    [No Abstract]   [Full Text] [Related]  

  • 54. Prevalence of adverse events in cystic fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor: Experience of the regional referral center in Tuscany, Italy.
    Manciulli T; Bresci S; Mencarini J; Avarello A; Taccetti G; Terlizzi V
    Pediatr Pulmonol; 2023 Dec; 58(12):3626-3629. PubMed ID: 37750598
    [No Abstract]   [Full Text] [Related]  

  • 55. Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis.
    Shakir S; Echevarria C; Doe S; Brodlie M; Ward C; Bourke SJ
    J Cyst Fibros; 2022 Sep; 21(5):807-810. PubMed ID: 35718668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy.
    Heo S; Young DC; Safirstein J; Bourque B; Antell MH; Diloreto S; Rotolo SM
    J Cyst Fibros; 2022 Mar; 21(2):339-343. PubMed ID: 34742667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis.
    Donaldson SH; Corcoran TE; Pilewski JM; Mogayzel P; Laube BL; Boitet ER; Harris ES; Ceppe A; Edwards LJ; Zeman K; Wu J; Esther CR; Nichols DP; Bennett WD; Rowe SM
    J Cyst Fibros; 2024 Jan; 23(1):155-160. PubMed ID: 37845149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
    Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
    Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.